Story perspectives

FDA Rejects Replimune's Skin Cancer Treatment; Stock Plummets 58%

4/11/2026

Summary

Story summary

The U.S. Food and Drug Administration rejected Replimune Group's experimental treatment for advanced skin cancer.
The denial, the second in a row, cites insufficient data and reliance on a single-arm study.
Replimune's Chief Executive Officer expressed disappointment, contending the therapy demonstrated strong efficacy and safety.
Investors pushed Replimune's stock down 58% following the decision.
Vinay Prasad, regulatory expert, says the case signals stricter evidence for future biotech approvals.

History

Historical Context

The Kefauver-Harris Amendment of 1962 transformed FDA drug approval by mandating proof of efficacy, a response to the thalidomide disaster that caused severe birth defects. This shift towards rigorous testing has led to a cautious approach in biotech approvals, as seen in Replimune Group's recent rejection, emphasizing patient safety but potentially hindering innovation in drug development.

1 of 2

Story summary

The U.S. Food and Drug Administration rejected Replimune Group's experimental treatment for advanced skin cancer.
The denial, the second in a row, cites insufficient data and reliance on a single-arm study.
Replimune's Chief Executive Officer expressed disappointment, contending the therapy demonstrated strong efficacy and safety.
Investors pushed Replimune's stock down 58% following the decision.
Vinay Prasad, regulatory expert, says the case signals stricter evidence for future biotech approvals.

1 / 2